RESEARCH TRIANGLE PARK, N.C., Sept. 24, 2009 (GLOBE NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today announced the initiation of a proof-of-concept study of ICA-105665 in patients with photosensitive epilepsy. ICA-105665 is a novel, orally available opener of subtypes of KCNQ channels, which have been validated by both genetic and physiologic evidence as playing an important role in certain conditions characterized by abnormal neuroexcitability, such as seizures, and potentially also chronic pain disorders.
